Abdullah Al Rafi

Mr. Abdullah Al Rafi

Biochemistry and Biotechnology, University of Science and Technology Chittagong, Chittagong, Bangladesh
orcid
Undergraduate Researcher

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JEJannatul Nayma Eshita
Jannatul Nayma Eshita
AMAbu Bakar Al Mizan
Abu Bakar Al Mizan
IYIstekab Bin Yousuf
Istekab Bin Yousuf
TSTazeen Tarannum Sadia
Tazeen Tarannum Sadia
SMSidratul Muntaha
Sidratul Muntaha
DMDebabrata Mallick
Debabrata Mallick
To examine long-term trends in the prevalence and burden of diabetes among adults in Bangladesh from 2000 to 2050 using historical estimates and future projections.A descriptive epidemiological trend analysis using secondary data from the International Diabetes Federation (IDF) Diabetes Atlas (2000, 2011, 2024, and 2050 projections) and prevalence estimates calibrated with the Bangladesh Demographic and Health Survey (BDHS) 2017– 2018.Bangladesh, South-East Asia Region. Adults aged 20–79 years included in IDF diabetes estimates; additional population-level prevalence information drawn from BDHS. Number of adults with diabetes and age-standardised diabetes prevalence. The number of adults (20–79 years) with diabetes increased from 1.8 million in 2000 to 13.9 million in 2024, and is projected to reach 23.1 million by 2050. Age-standardised prevalence rose from 10.5% in 2011 to 13.2% in 2024, with a further increase to 15.4% projected for 2050. In 2024, 39.1% of adults with diabetes remained undiagnosed. Impaired fasting glucose and impaired glucose tolerance affected 19.1 million and 14.5 million adults respectively in 2024, with substantial projected increases by 2050. Bangladesh ranks second highest in the South-East Asia Region in both prevalence and total number of adults with diabetes, following India. Diabetes-related mortality accounted for 31,619 deaths in 2024, and health expenditure reached USD 1.03 billion, increasing further in future projections. Bangladesh faces a rapidly escalating diabetes epidemic, marked by sharp increases in prevalence, undiagnosed cases, metabolic risk conditions, and healthcare expenditure. Without immediate public health interventions particularly lifestyle modification programmes, expanded screening, and strengthened surveillance the diabetes burden is expected to rise substantially by 2050. STRENGTHS AND LIMITATIONS OF THIS STUDY: ⇒ We examined long-term changes in the diabetes burden among Bangladeshi adults from 2000 to 2024 and projections up to 2050. ⇒ Estimates were derived from nationally representative and internationally validated data sources, including BDHS and IDF. ⇒ This study uniquely combines historical trends with future forecasts to highlight the evolving epidemiology of diabetes. ⇒ All data were generated following standardize and WHO-aligned assessment methods. ⇒ Limited availability of continuous annual data and missing risk factor variables restricted deeper analytical exploration.

5 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
Abdullah Al RafiAbdullah Al Rafi
Abdullah Al Rafi
KOKashefatun Nur Orni
Kashefatun Nur Orni
TSTasnuba Ashraf Subah
Tasnuba Ashraf Subah
SASaima Akther
Saima Akther
AAAnkita Acharjee
Ankita Acharjee
DMDebabrata Mallick
Debabrata Mallick
Introduction: Among women in Bangladesh, breast and cervical cancers remain the most frequently diagnosed malignancies. To strengthen early detection, In 2005, a national VIA-based cervical cancer screening initiative was launched, followed later by the addition of CBE for breast cancer and later integrated Clinical Breast Examination (CBE) for breast cancer screening. Since 2013, the Ministry of Health and Family Welfare (MOHFW) has implemented an electronic reporting system based on DHIS2 for aggregated health data, complemented by a case-based reporting stream established under the National Centre for Cervical and Breast Cancer Screening and Training (NCCBCST). This study reviews and evaluates VIA, colposcopy, and CBE screening data from 2024–2025 to assess the effectiveness, reliability, and overall performance of the electronic reporting system. Methods: A descriptive approach was employed, using secondary data obtained from both the aggregated and case-based DHIS2 electronic databases. The study included women aged 30–60 years screened for cervical cancer using VIA and all women undergoing CBE across multiple levels of health facilities, including community clinics, upazila and district hospitals, medical colleges, tertiary hospitals, and BSMMU. Data from 2024–2025 were cleaned and analysed in Microsoft Excel to assess screening volumes, positivity rates, and division-wise variations. Aggregated and case-based datasets were compared to evaluate completeness, consistency, and functionality of the reporting system. Results: Across 2024–2025, a total of 917,845 VIA tests and 964,228 CBE tests were performed nationwide. The national VIA-positivity rate was 9.7%, with the highest rates observed in Mymensingh (12.1%) and Rangpur (11.4%). A total of 20,819 colposcopy tests were conducted, showing a high national colposcopy-positivity rate of 147.2%, indicating a substantial number of referrals originating outside routine VIA screening. CBE positivity averaged 4.9%, with notable regional variation—highest in Rangpur (7.1%) and lowest in Barishal (2.9%). Screening participation was highest in the Dhaka division, whereas Sylhet consistently exhibited the lowest levels of service use. Aggregated and case-based reporting displayed strong alignment for key indicators, though referral pathway inconsistencies were observed. Conclusions: Electronic reporting through DHIS2 both aggregated and case-based proved effective for monitoring cervical and breast cancer screening activities in Bangladesh, enabling large-scale data capture, geographic analysis, and programme oversight. However, substantial inter-divisional disparities, low screening uptake in specific regions, and referral-linkage gaps between VIA and colposcopy highlight areas for improvement. Improving quality control mechanisms, adopting unique identifiers, and reinforcing referral pathways could enhance overall equity and efficiency of the national cancer-prevention programme.

24 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
Sohel RanaSohel Rana
Sohel Rana
MHMd. Sanowar Hossan
Md. Sanowar Hossan
Abdullah Al RafiAbdullah Al Rafi
Abdullah Al Rafi
DHDeri Damien Hagidok
Deri Damien Hagidok
AKAlok Kumer
Alok Kumer
RARasel A. Al-Amin
Rasel A. Al-Amin
Protein arginine methyltransferase 5 (PRMT5) is a promising anticancer target, yet existing inhibitors shown limited clinical efficacy. Here, we paired multi-omics pan-cancer profiling with a machine learning virtual screening pipeline. Bioinformatics analyses with TIMER3, GEPIA2, UALCAN/CPTAC, the Human Protein Atlas, cBioPortal, STRING and Enrichr revealed widespread of PRMT5 mRNA expression, protein abundance, survival, genetic alteration, immune infiltration and co-expression networks with tumor-specific prognostic impact in GBM, LGG and KIRC. A deep neural network screened about 1.5 million PubChem compounds and deep neural network reached a ROC-AUC = 0.9857 and prioritized three candidates, CID 44345182, CID 2794188 and CID 44345334. Subsequent molecular docking against PRMT5 (PDB ID: 4X61), ADMET filtering and toxicity prediction, and 100 ns molecular dynamics (MD) simulations identified CID 44345182 as the potential hit, similar the docking scores of −9.8 compared with - 9.2 kcal/mol for the reference ligand in binding affinity and trajectory stability. These findings clarify the context-dependent roles of PRMT5 and further experiment validations are needed to establish CID 44345182 as a promising candidate.